company background image
PHIL logo

Philogen BIT:PHIL Stock Report

Last Price

€19.95

Market Cap

€803.8m

7D

-4.1%

1Y

25.5%

Updated

18 Jun, 2024

Data

Company Financials +

PHIL Stock Overview

A biotechnology company, develops drugs for oncology and chronic inflammatory diseases.

PHIL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Philogen S.p.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Philogen
Historical stock prices
Current Share Price€19.95
52 Week High€21.60
52 Week Low€14.90
Beta0.18
1 Month Change10.83%
3 Month Change12.71%
1 Year Change25.47%
3 Year Change38.93%
5 Year Changen/a
Change since IPO19.53%

Recent News & Updates

Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher

Apr 14
Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher

Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates

Mar 31
Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates

Recent updates

Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher

Apr 14
Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher

Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates

Mar 31
Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates

What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You

Feb 24
What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You

Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation

Jun 03
Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation

Shareholder Returns

PHILIT BiotechsIT Market
7D-4.1%-1.4%-1.6%
1Y25.5%-11.1%16.8%

Return vs Industry: PHIL exceeded the Italian Biotechs industry which returned -11.1% over the past year.

Return vs Market: PHIL exceeded the Italian Market which returned 16.8% over the past year.

Price Volatility

Is PHIL's price volatile compared to industry and market?
PHIL volatility
PHIL Average Weekly Movement3.8%
Biotechs Industry Average Movement6.9%
Market Average Movement4.3%
10% most volatile stocks in IT Market7.8%
10% least volatile stocks in IT Market2.8%

Stable Share Price: PHIL has not had significant price volatility in the past 3 months.

Volatility Over Time: PHIL's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996165Dario Neriwww.philogen.com

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase II clinical trial for the treatment of chronic inflammatory disorders; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressed on the surface of solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial.

Philogen S.p.A. Fundamentals Summary

How do Philogen's earnings and revenue compare to its market cap?
PHIL fundamental statistics
Market cap€803.78m
Earnings (TTM)-€6.16m
Revenue (TTM)€24.73m

32.5x

P/S Ratio

-130.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHIL income statement (TTM)
Revenue€24.73m
Cost of Revenue€17.46m
Gross Profit€7.27m
Other Expenses€13.43m
Earnings-€6.16m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Sep 25, 2024

Earnings per share (EPS)-0.15
Gross Margin29.39%
Net Profit Margin-24.91%
Debt/Equity Ratio3.1%

How did PHIL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.